The research compound in Saxenda®
Saxenda® is a chronic weight management medicine from Novo Nordisk. Its active compound is Liraglutide — which is what this catalogue supplies, as a research material.
This is not Saxenda®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Liraglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Saxenda® is a trademark of Novo Nordisk, referenced here only to identify the compound.
Saxenda is Novo Nordisk’s brand for liraglutide in weight management; the same compound is marketed as Victoza for type 2 diabetes.
Liraglutide is a GLP-1 receptor agonist carrying a C16 fatty acid chain, giving it a half-life around 13 hours — daily rather than weekly.
Liraglutide is supplied here as a research material with batch documentation.
Liraglutide in this catalogue
0.6mg × 5 pens
Other brands using Liraglutide
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.